Dolphin Entertainment Inc. shares rose up to 236% on NASDAQ
The National Association of Securities Dealers Automated Quotations (NASDAQ) Composite Index opened at 13,381.43 and closed at 13,227.70 on 23rd March 2021. The highest it touched was 13,405.14 and lowest 13,202.43
Today’s top 5 Performers:
Dolphin Entertainment Inc. (Change% 236.33 priced at $16.7)
Dolphin Entertainment, Inc. engages in the provision of entertainment marketing and content development. It operates through the following Entertainment Publicity and Marketing ; and Content Production segments. The Entertainment Publicity and Marketing segment comprises of 42West, The Door, Viewpoint, and Shore Fire Media. The Content Production segment consists of Dolphin Entertainment and Dolphin Films. The company was founded on March 7, 1995 and is headquartered in Coral Gables, FL.
Benitec Biopharma Ltd. ADR (Change% 190.28 priced at $7.9)
Benitec Biopharma, Inc. engages in the discovery, development, and commercialization of therapeutic agents by applying the silence and replace approach to the treatment of genetic disorders. It is a development-stage biotechnology company which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, CA.
Liquid Media Group Ltd. (Change% 22.92 priced at $5)
Liquid Media Group Ltd. is a media and entertainment company, which engages in content IP spanning creative industries. It develops, produces, and distributes content across channels, and platforms. It operates through the following segments: Film and Video Games. The company was founded on August 9, 2018 and headquartered in Vancouver, Canada.
Oncolytics Biotech Inc. (Change% 17.26 priced at $3.5)
Hoth Therapeutics Inc. (Change% 15.14 priced at $2.4)
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
